Investment: PPL prospects uncertain
Thursday 12 November 1998
The company plans to spend the bulk of the pounds 20.4m raised in the six-for- five issue to fund development of BSSL, its cystic fibrosis and pancreatitis drug, and Factor IX, a haemophilia treatment, to be launched in 2002-3. These compounds, like all PPL's drugs, are derived from the milk of genetically engineered sheep such as Polly, Dolly's successor.
This is an innovative technology and could lead to the development of more user-friendly and less costly medicines. But does it work? The answer will come in the first quarter of next year, when PPL is due to publish the results of a trial for the anti-cystic fibrosis drug AAT, its most advanced and most promising product.
A positive result would also speed negotiations with two mystery pharmaceutical partners to launch AAT in 2001. If the sheep's milk technology is shown to work with AAT, then PPL with its focused pipeline, multi-million pound potential markets and reasonably good balance sheet, could become one of the biotech successes of the next millennium. If it fails, PPL will look fragile. Given the uncertainty over the company's prospects, the shares are no more than a hold.
- 1 Howard Jacobson: Let's see the 'criticism' of Israel for what it really is
- 3 Belgium fan Axelle Despiegelaere lands L'Oreal campaign after World Cup viral photo
- 4 Britney Spears sings 'Alien' without Auto-Tune in embarrassingly brilliant leaked audio clip
- 5 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
‘Ryan Gosling got someone pregnant and it's not me. Brazil you think you’re devastated…’
Israel-Palestine crisis: ‘We just want it to end… We don’t deserve to live like this’
Israel-Palestine crisis: Eight killed in Gaza Strip cafe while watching World Cup semi-final
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
There’s a nasty smell in the political air – and it’s coming from the Tories
Vanessa Feltz criticises 'vile' reaction to Rolf Harris allegations
iJobs Money & Business
£60000 - £75000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
£60000 per annum: Harrington Starr: A leading provider in investment managemen...
£600 - £700 per day: Harrington Starr: AVS, JVS Openlink Endur Developer JVS, ...
£30000 per annum: Harrington Starr: A global leader in trading platforms and e...